Strata Skin Sciences, Inc. (SSKN) Financial Statements (2024 and earlier)

Company Profile

Business Address 5 WALNUT GROVE DRIVE
HORSHAM, PA 19044
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,43412,58610,6048,12916,4874,069
Cash and cash equivalents5,43412,58610,6048,12916,4874,069
Restricted cash and investments1,361 7,5087,500  
Receivables4,4713,4332,9444,3863,3933,141
Inventory, net of allowances, customer advances and progress billings5,5473,4893,4443,0272,7943,009
Inventory5,5473,4893,4443,0272,7943,009
Other undisclosed current assets691462331513536533
Total current assets:17,50419,97024,83123,55523,21010,752
Noncurrent Assets
Operating lease, right-of-use asset9756389881,314
Property, plant and equipment7,4986,8835,5295,3695,3017,703
Intangible assets, net (including goodwill)26,19718,88615,14816,75818,56820,128
Goodwill8,8038,8038,8038,8038,8038,803
Intangible assets, net (excluding goodwill)17,39410,0836,3457,9559,76511,325
Other noncurrent assets9821628234742848
Total noncurrent assets:34,76826,62321,94723,78824,29727,879
TOTAL ASSETS:52,27246,59346,77847,34347,50738,631
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,9809,1997,4547,0146,2644,637
Accounts payable3,4252,8222,7641,8801,7642,277
Accrued liabilities6,5556,3774,6905,1344,5002,360
Deferred revenue2,7783,2852,2622,8322,099
Debt   8,7533132522,387
Deferred revenue and credits291
Other undisclosed current liabilities6683183697,275 357
Total current liabilities:13,42612,80218,83817,4348,6157,672
Noncurrent Liabilities
Long-term debt and lease obligation7,4767,7111,7601,0787,1457,853
Long-term debt, excluding current maturities7,4767,3191,050 7,1457,853
Liabilities, other than long-term debt1,187300288178388861
Accounts payable and accrued liabilities7120    
Deferred revenue20014  
Deferred tax liabilities, net 414
Deferred income tax liabilities306266254 
Other liabilities   34178388444
Operating lease, liability6103927101,078
Derivative instruments and hedges, liabilities      3
Other undisclosed noncurrent liabilities8,352366  111 
Total noncurrent liabilities:17,0158,3772,0481,2567,6448,714
Total liabilities:30,44121,17920,88618,69016,25916,386
Equity
Equity, attributable to parent, including:21,83125,41425,89228,65331,24822,245
Common stock35343433304
Additional paid in capital249,024247,059244,831243,180241,988251,643
Accumulated deficit(227,228)(221,679)(218,973)(214,561)(210,771)(229,406)
Other undisclosed equity, attributable to parent    114
Total equity:21,83125,41425,89228,65331,24822,245
TOTAL LIABILITIES AND EQUITY:52,27246,59346,77847,34347,50738,631

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues36,16129,97723,09031,58629,85531,449
Revenue, net31,449
Cost of revenue(14,393)(10,127)(8,956)(11,316)(12,735)(13,498)
Gross profit:21,76819,85014,13420,27017,12017,951
Operating expenses(26,417)(24,252)(18,210)(23,280)(20,475)(20,361)
Operating loss:(4,649)(4,402)(4,076)(3,010)(3,355)(2,410)
Nonoperating income (expense)(837)1,730(61)(929)(942)(16,292)
Other nonoperating income     20017
Interest and debt expense(926)2,029 (414)(1,142)(11,799)
Other undisclosed income from continuing operations before equity method investments, income taxes    4141,14211,799
Loss from continuing operations before equity method investments, income taxes:(6,412)(643)(4,137)(3,939)(4,297)(18,702)
Other undisclosed income (loss) from continuing operations before income taxes926(2,029)    
Loss from continuing operations before income taxes:(5,486)(2,672)(4,137)(3,939)(4,297)(18,702)
Income tax expense (benefit) (63)(34)(275)149264(129)
Other undisclosed loss from continuing operations      
Loss from continuing operations:(5,549)(2,706)(4,412)(3,790)(4,033)(18,831)
Loss before gain (loss) on sale of properties:(2,706)(4,412)(3,790)(4,033)(18,831)
Net loss:(5,549)(2,706)(4,412)(3,790)(4,033)(18,831)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(5,549)(2,706)(4,412)(3,790)(4,033)(18,831)
Other undisclosed net income available to common stockholders, basic    1931,124 
Net loss available to common stockholders, basic:(5,549)(2,706)(4,412)(3,597)(2,909)(18,831)
Interest on convertible debt      3,117
Net loss available to common stockholders, diluted:(5,549)(2,706)(4,412)(3,597)(2,909)(15,714)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(5,549)(2,706)(4,412)(3,790)(4,033)(18,831)
Comprehensive loss:(5,549)(2,706)(4,412)(3,790)(4,033)(18,831)
Other undisclosed comprehensive loss, net of tax, attributable to parent      (2)
Comprehensive loss, net of tax, attributable to parent:(5,549)(2,706)(4,412)(3,790)(4,033)(18,833)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: